Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because the technology is an option alongside current standard treatment options and is available at a similar price.
The list price of guselkumab has a discount that is commercial in confidence. For enquiries about the patient access scheme, contact:
- Jennifer Lee, Director of HEMAR and Advocacy, jlee267@ITS.JNJ.com
- Amish Chaturvedi, HEMAR Lead, achatur6@ITS.JNJ.com
A resource impact template is provided for completion at local level. This is because there are now several treatment options (biological and non-biological therapies) that are recommended by NICE for plaque psoriasis, which can be branded or be a biosimilar.
Therefore, organisations should complete both current and future uptake based on local practice.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
Because guselkumab has been recommended through the fast track appraisal process, NHS England and commissioning groups have committed to providing funding to implement this guidance 30 days after publication.
This page was last updated: 13 June 2018